Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Tuberculosis

Free Subscription Articles published in J Antimicrob Chemother Retrieve available abstracts of 17 articles: HTML format

Single Articles

May 2025
1. KOELE SE, Heinrich N, De Jager VR, Dreisbach J, et al
   Population pharmacokinetics and exposure-response relationship of the antituberculosis drug BTZ-043.
   J Antimicrob Chemother. 2025;80:1315-1323.
   PubMed     Abstract available
   
   
   April 2025
2. METARFI Y, Chellal W, Ben Khadda Z, Hoummani H, et al
   Therapeutic drug monitoring in anti-tuberculosis treatment: a systematic review.
   J Antimicrob Chemother. 2025 Apr 21:dkaf126. doi: 10.1093.
   PubMed     Abstract available
   
   
   
3. KANG SW, Jang HM, Chang E, Bae S, et al
   Impact of fluoroquinolone exposure on the diagnosis and prognosis of tuberculosis in immunocompromised patients: a propensity-score-matched, competing risk analysis.
   J Antimicrob Chemother. 2025 Apr 7:dkaf111. doi: 10.1093.
   PubMed     Abstract available
   
   
   February 2025
4. LIU W, Xu N, Li W, Mak WY, et al
   Pharmacokinetics and safety of rifapentine in children: dosing for latent tuberculosis infection.
   J Antimicrob Chemother. 2025 Feb 13:dkaf029. doi: 10.1093.
   PubMed     Abstract available
   
   
   January 2025
5. CHEN S, Shang Y, Zheng J, Huo F, et al
   In vitro monitoring of drug resistance emergence during stepwise induction of bedaquiline and clofazimine, alone and in combination: a phenotypic and genotypic analysis.
   J Antimicrob Chemother. 2025;80:262-269.
   PubMed     Abstract available
   
   
   December 2024
6. LI X, Qi X, Wang B, Fu L, et al
   Efficacy of nintedanib as a host-directed therapy candidate in the treatment of tuberculosis.
   J Antimicrob Chemother. 2024 Dec 4:dkae429. doi: 10.1093.
   PubMed     Abstract available
   
   
   November 2024
7. AGIBOTHU KUPPARAM HK, Shah I, Chandrasekaran P, Mane S, et al
   Pharmacokinetics of anti-TB drugs in children and adolescents with drug-resistant TB: a multicentre observational study from India.
   J Antimicrob Chemother. 2024;79:2939-2947.
   PubMed     Abstract available
   
   
   October 2024
8. LIN YJ, Zou Y, Karlsson MO, Svensson EM, et al
   A pharmacometric multistate model for predicting long-term treatment outcomes of patients with pulmonary TB.
   J Antimicrob Chemother. 2024;79:2561-2569.
   PubMed     Abstract available
   
   
   August 2024
9. WALTER K, Te Brake LHM, Lemm AK, Hoelscher M, et al
   Investigating the treatment shortening potential of a combination of bedaquiline, delamanid and moxifloxacin with and without sutezolid, in a murine tuberculosis model with confirmed drug exposures.
   J Antimicrob Chemother. 2024 Aug 7:dkae266. doi: 10.1093.
   PubMed     Abstract available
   
   
   
10. WIJK M, Gausi K, Malatesta S, Weber SE, et al
    The impact of alcohol and illicit substance use on the pharmacokinetics of first-line TB drugs.
    J Antimicrob Chemother. 2024;79:2022-2030.
    PubMed     Abstract available
    
    
    June 2024
11. KARAKITSIOS E, Dokoumetzidis A
    Extrapolation of lung pharmacokinetics of antitubercular drugs from preclinical species to humans using PBPK modelling.
    J Antimicrob Chemother. 2024;79:1362-1371.
    PubMed     Abstract available
    
    
    April 2024
12. PHAISAL W, Albitar O, Chariyavilaskul P, Jantarabenjakul W, et al
    Genetic and clinical predictors of rifapentine and isoniazid pharmacokinetics in paediatrics with tuberculosis infection.
    J Antimicrob Chemother. 2024 Apr 25:dkae059. doi: 10.1093.
    PubMed     Abstract available
    
    
    
13. STEMKENS R, Mouhdad C, Franssen EJF, Touw D, et al
    Ten-year results of an international external quality control programme for measurement of anti-tuberculosis drug concentrations.
    J Antimicrob Chemother. 2024 Apr 6:dkae105. doi: 10.1093.
    PubMed     Abstract available
    
    
    
14. VAN INGEN J
    Why do we use 100 mg of clofazimine in TB and NTM treatment?
    J Antimicrob Chemother. 2024;79:697-702.
    PubMed     Abstract available
    
    
    March 2024
15. YUNIVITA V, Gafar F, Santoso P, Chaidir L, et al
    Pharmacokinetics and pharmacodynamics of high-dose isoniazid for the treatment of rifampicin- or multidrug-resistant tuberculosis in Indonesia.
    J Antimicrob Chemother. 2024 Mar 9:dkae057. doi: 10.1093.
    PubMed     Abstract available
    
    
    December 2023
16. COMBRINCK J, Tshavhungwe P, Rohlwink U, Enslin N, et al
    Rifampicin and protein concentrations in paired spinal versus ventricular cerebrospinal fluid samples of children with tuberculous meningitis.
    J Antimicrob Chemother. 2023 Dec 15:dkad371. doi: 10.1093.
    PubMed     Abstract available
    
    
    September 2023
17. MOK S, Roycroft E, Flanagan PR, Wagener J, et al
    Investigation of genomic mutations and their association with phenotypic resistance to new and repurposed drugs in Mycobacterium tuberculosis complex clinical isolates.
    J Antimicrob Chemother. 2023 Sep 23:dkad252. doi: 10.1093.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Tuberculosis is free of charge.